Nuformix Plc (GB:NFX)
LSE:NFX
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.57M
Enterprise Value3.59M
Total Cash (Recent Filing)£97.55K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-free balance sheet materially reduces financial risk and preserves strategic flexibility. Over the medium term this lowers bankruptcy risk, makes partnership or licensing negotiations simpler, and gives management optionality to raise equity or structure non-debt financing without servicing constraints.
Repurposing Business ModelA strategy centered on repurposing/reformulation typically shortens development timelines and lowers clinical/technical risk versus novel molecular entities. This durable model improves the odds of attracting partners and out-licensing deals, aligning costs and capital needs with milestone-driven partnering.
Improved 2025 Loss ProfileA materially smaller loss in 2025 versus 2024 suggests management has tightened spending or removed one-offs. If sustained, improved cost discipline prolongs runway, reduces near-term funding pressure, and increases the chance of reaching value-generating development milestones with lower incremental capital.
Bears Say
No Recent RevenueLack of revenue across multiple years indicates the company has no commercialized products and cannot self-fund operations. This structural revenue gap increases reliance on external capital or partners, raising execution and dilution risk and slowing progress toward sustainable operations.
Persistent Cash BurnConsistent negative operating and free cash flow means the business requires ongoing financing to continue development. Over the medium term this restricts strategic autonomy, forces fundraising cadence, and can delay trials or partnerships if funding terms deteriorate or are unavailable when needed.
Shrinking Equity / Small Asset BaseA materially reduced equity and asset base leaves a limited financial buffer against setbacks. This structural fragility reduces collateral for financing, increases the likelihood of equity dilution or restructuring, and heightens vulnerability to cost overruns or delays in partner-led financing.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.57M.
When is Nuformix Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuformix Plc’s earnings last quarter?
Currently, no data Available
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―